Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis
about
Pathogenesis of Aspergillus fumigatus in Invasive AspergillosisAspergillus fumigatus: principles of pathogenesis and host defenseInterference of Aspergillus fumigatus with the immune responseInvasive aspergillosis in the intensive care unitA sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatusIn vivo hypoxia and a fungal alcohol dehydrogenase influence the pathogenesis of invasive pulmonary aspergillosisInnate immunity to Aspergillus species.NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Chemically induced disseminated pythiosis in BALB/c mice: A new experimental model for Pythium insidiosum infection.HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatusCD8⁺ T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis.Peptide-based Antifungal Therapies against Emerging Infections.Embryonated eggs as an alternative infection model to investigate Aspergillus fumigatus virulence.Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites.Immunoproteomics based identification of thioredoxin reductase GliT and novel Aspergillus fumigatus antigens for serologic diagnosis of invasive aspergillosis.Persistence versus escape: Aspergillus terreus and Aspergillus fumigatus employ different strategies during interactions with macrophages.Overview of vertebrate animal models of fungal infection.Role of Aspergillus fumigatus DvrA in host cell interactions and virulenceMyeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infectionDistinct innate immune phagocyte responses to Aspergillus fumigatus conidia and hyphae in zebrafish larvae.Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence.Establishment and application of real-time quantitative PCR for diagnosing invasive aspergillosis via the blood in hematological patients: targeting a specific sequence of Aspergillus 28S-ITS2.Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosisPretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsAspergillus terreus accessory conidia are multinucleated, hyperpolarizing structures that display differential dectin staining and can induce heightened inflammatory responses in a pulmonary model of aspergillosis.Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens.Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone.Cytokines and fungal infections.Protective Effector Cells of the Recombinant Asp f3 Anti-Aspergillosis Vaccine.Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/ MSG and ICU criteria.Invasive fungal disease in university hospital: a PCR-based study of autopsy cases.Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective studyProangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosisAdvances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders.Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.Animal models: an important tool in mycology.
P2860
Q24650911-B586792C-F779-4DA4-A7B9-61A505485C21Q24681995-B3056DF5-8BC3-4509-A9AF-58A6477062F6Q26865553-DEBDB143-5BA1-45E5-9789-09C66BB5DDBDQ28306909-F4EC5C60-0598-4D1C-86A5-A35CECB02DE6Q28473962-BDB7B060-F067-4162-A18A-BA072B1A689FQ28479237-7E247EA2-5F5C-4344-A931-3DAA3823417DQ30434628-CB3BADED-20AB-45BA-B9C4-5081AB6ECA43Q33552719-B54066F3-3147-4D1A-A17F-BDDAACF189DCQ33689767-B4E20FF3-2967-416D-B91F-583303320D70Q33707923-D55DFBBD-9754-43A4-9CDB-3E546683E459Q33716978-954B82E2-D267-4B21-82DD-AC995BA2DFECQ33754548-9147730A-859B-47C0-B4A2-A3FD0D49FA9FQ33862289-F24E5E4F-0E8F-4D9E-841B-3063AC251A9FQ33963128-12CB52B6-7580-47F2-958A-D1915A281668Q34078418-BF6ECEE2-6006-4BC0-AB24-E1E206BB0D50Q34129471-EA88339B-0F8F-48A6-9CF8-8DFB3082944AQ34154790-B3007400-3C61-4F2E-999E-E06FCC6A6716Q34175500-D430F7E1-088C-4C07-8C03-368D8DAAB31DQ34177616-83E5C746-D244-481B-A379-7E46DD427DE9Q34257883-4969CBB8-12EB-4349-B4E0-E6C08679E59EQ34297696-B247D802-8842-49E5-931B-40AA838ED4FFQ34352222-A5C8A408-BAFB-4A0E-B736-FB19C3581A90Q34736784-EF083029-A351-4B73-935E-2ADD534EFDFFQ34750807-05F414B1-376E-4F57-8E47-DAF269D4C495Q35065748-9CC84DEB-87BF-4D5F-84F7-74FA36E1CD5AQ35647688-90EF996C-79B5-4453-8677-93EC9CC3CBF8Q35666612-1508A989-55EB-4228-A7CA-48BA76E3682AQ35693744-3607E483-D5CD-4119-B1E0-1949D08978D1Q35758926-F0313DAB-A992-4F10-B5DA-5CE74F4A97B4Q35845437-DB5D8854-8488-45B7-87CD-6B14CE51D54EQ36095263-C5CE87E5-9009-4093-9A1C-293713839067Q36139494-BB3FE8F8-8766-4D7B-A2D8-A021D509B487Q36231936-E545E9C6-129B-46D0-868E-772849D3FD5FQ36307784-A9144C4B-8429-4AE7-BFC9-1C95A2145334Q36464676-25826745-7A6C-4C4E-B9DE-595C8CF1A699Q36633947-AD8D4D56-A76D-428C-B532-4AD88B21F15CQ36641630-2B483756-8AC4-43E6-B5D4-94274A684AA1Q36774247-DC62D9C1-655D-4746-85AC-14E220DA0CEDQ36974215-E1837B40-8035-4EAF-BEE8-B55EBE31333FQ37008692-5F72FB54-6A4C-437F-9E77-6AF6C820765F
P2860
Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Differences in patterns of inf ...... vasive pulmonary aspergillosis
@en
type
label
Differences in patterns of inf ...... vasive pulmonary aspergillosis
@en
prefLabel
Differences in patterns of inf ...... vasive pulmonary aspergillosis
@en
P2093
P2860
P921
P1476
Differences in patterns of inf ...... vasive pulmonary aspergillosis
@en
P2093
Jean-Paul Latgé
Michel Chignard
Viviane Balloy
P2860
P304
P356
10.1128/IAI.73.1.494-503.2005
P407
P577
2005-01-01T00:00:00Z